Parrish Capital LLC Has $2.28 Million Stock Position in Astrazeneca Plc $AZN

Parrish Capital LLC reduced its holdings in shares of Astrazeneca Plc (NYSE:AZN) by 55.0% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,555 shares of the company’s stock after selling 14,111 shares during the period. Astrazeneca accounts for about 2.0% of Parrish Capital LLC’s investment portfolio, making the stock its 8th largest holding. Parrish Capital LLC’s holdings in Astrazeneca were worth $2,279,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Brighton Jones LLC grew its stake in shares of Astrazeneca by 93.2% in the 4th quarter. Brighton Jones LLC now owns 5,782 shares of the company’s stock worth $379,000 after buying an additional 2,789 shares during the last quarter. AQR Capital Management LLC raised its stake in Astrazeneca by 45.3% during the first quarter. AQR Capital Management LLC now owns 37,501 shares of the company’s stock valued at $2,756,000 after buying an additional 11,690 shares during the last quarter. Amundi raised its stake in Astrazeneca by 54.4% during the second quarter. Amundi now owns 10,274 shares of the company’s stock valued at $731,000 after buying an additional 3,618 shares during the last quarter. Jump Financial LLC boosted its holdings in Astrazeneca by 898.4% in the second quarter. Jump Financial LLC now owns 33,478 shares of the company’s stock worth $2,339,000 after acquiring an additional 30,125 shares in the last quarter. Finally, Daiwa Securities Group Inc. boosted its holdings in Astrazeneca by 1.2% in the second quarter. Daiwa Securities Group Inc. now owns 46,642 shares of the company’s stock worth $3,259,000 after acquiring an additional 559 shares in the last quarter. Institutional investors own 20.35% of the company’s stock.

Astrazeneca Trading Down 0.1%

Shares of AZN stock opened at $194.96 on Friday. The company has a current ratio of 0.91, a quick ratio of 0.71 and a debt-to-equity ratio of 0.52. Astrazeneca Plc has a 12-month low of $137.23 and a 12-month high of $212.71. The stock has a market capitalization of $302.36 billion, a P/E ratio of 29.27, a P/E/G ratio of 1.58 and a beta of 0.24. The firm’s 50 day moving average is $183.96 and its 200 day moving average is $188.09.

Astrazeneca (NYSE:AZN) last announced its earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.52 by $0.06. The business had revenue of $15.29 billion during the quarter, compared to analyst estimates of $14.93 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. Research analysts expect that Astrazeneca Plc will post 10.28 earnings per share for the current year.

Wall Street Analyst Weigh In

AZN has been the subject of several analyst reports. The Goldman Sachs Group restated a “buy” rating on shares of Astrazeneca in a report on Wednesday. Morgan Stanley reiterated an “overweight” rating on shares of Astrazeneca in a research note on Wednesday, April 8th. TD Cowen reissued a “buy” rating on shares of Astrazeneca in a research report on Wednesday, March 18th. Bank of America restated a “buy” rating on shares of Astrazeneca in a research note on Wednesday. Finally, Weiss Ratings cut shares of Astrazeneca from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, June 18th. Fourteen analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Astrazeneca currently has a consensus rating of “Moderate Buy” and a consensus price target of $205.33.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.